EURURO Vol. 72 No. 3

FM4 476

CONTENTS
e u r o p e a n u r o l o g y , vo l . 7 2 , n o . 3 , S e p t emb e r 2 0 1 7
e51 The Platinum Hall of Fame
321
L. Henningsohn, N. Dastaviz, N. Stathakarou, C. McGrath
KIUrologyX is a massive open online course in clinical urology that allows a broad
range of people access to important clinical knowledge. It is a course that can be
made available to an unlimited number of students, professionals, patients,
and their kin.
323
M.T. Schweizer, E.S. Antonarakis, S.R. Denmeade
Bipolar androgen therapy (BAT) is a paradoxical treatment for castrate-resistant
prostate cancer whereby testosterone levels are rapidly alternated between
supraphysiologic and near-castrate concentrations. Initial studies demonstrated
that BAT is safe and produces clinical responses. A trial comparing enzalutamide
against BAT is ongoing.
326
M.R. Cooperberg
The US Preventive Services Task Force has issued a new draft guideline, with a “C”
recommendation that men aged 55–69 yr should be informed about the benefits
and harms of screening for prostate cancer, and offered prostate-specific antigen
testing if they choose it. For men aged ≥70 yr, the recommendation remains “D”, or
“do not screen.” This draft represents substantial progress in the right direction
towards offering men a fair opportunity to discuss the risks and benefits of
screening with their primary care providers. However, the evidence review
underlying the draft remains fundamentally inadequate, leading to biased
presentations of both benefits and harms of screening. The final guideline and future
revisions should reflect formal engagement with subject matter experts to optimize
the advise given to men and their physicians.
329
M.S. Leapman, N. Ameli, M.R. Cooperberg, C. Chu, A. Hussein, K. Shinohara, P.R. Carroll
For men with prostate cancer managed with active surveillance, changes in clinical
risk over time are nonuniform and may be regarded along a spectrum. Among men
ultimately receiving definitive treatment with prostatectomy, the magnitude of
clinical risk change from baseline was associated with risk of high-grade and/or
high-stage disease. Reclassification should be considered on the basis of multiple
clinical variables.
PlatinumOpinions
Brief Correspondence